Biodesix (NASDAQ:BDSX) had its price objective boosted by Canaccord Genuity from $26.00 to $27.00 in a research report released on Monday morning, The Fly reports. They currently have a buy rating on the stock.
Several other research firms have also issued reports on BDSX. Morgan Stanley began coverage on shares of Biodesix in a report on Monday, November 23rd. They set an overweight rating and a $20.00 target price for the company. William Blair initiated coverage on shares of Biodesix in a report on Monday, November 23rd. They set an outperform rating for the company. Finally, BTIG Research initiated coverage on shares of Biodesix in a report on Monday, November 23rd. They issued a buy rating and a $22.00 price objective for the company.
Biodesix stock opened at $23.78 on Monday. The firm’s 50 day moving average price is $17.88. Biodesix has a fifty-two week low of $10.85 and a fifty-two week high of $24.25.
Biodesix (NASDAQ:BDSX) last released its earnings results on Thursday, December 10th. The company reported ($31.93) earnings per share (EPS) for the quarter. The firm had revenue of $9.19 million for the quarter, compared to analysts’ expectations of $7.78 million. On average, equities research analysts anticipate that Biodesix will post -5.66 earnings per share for the current year.
Biodesix Company Profile
Biodesix, Inc operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests provide physicians with timely results to facilitate treatment decisions.
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.